Seelos Therapeutics, Inc., a biotechnology company incorporated in Nevada and based in New York, has filed a Form D with the U.S. Securities and Exchange Commission (SEC) on February 14, 2024, indicating a new notice of an exempt offering of securities. The filing reveals that the company is offering options, warrants, or other rights to acquire another security, with the total offering amount listed as $3,574,468. This amount represents the aggregate exercise price of warrants to purchase shares of the company's common stock, which were issued in connection with a registered direct offering. The date of the first sale is reported as January 30, 2024, and the offering is not intended to last more than one year. Seelos Therapeutics has claimed an exemption...Show More

Seelos Therapeutics, Inc., a biotechnology company incorporated in Nevada and based in New York, has filed a Form D with the U.S. Securities and Exchange Commission (SEC) on February 14, 2024, indicating a new notice of an exempt offering of securities. The filing reveals that the company is offering options, warrants, or other rights to acquire another security, with the total offering amount listed as $3,574,468. This amount represents the aggregate exercise price of warrants to purchase shares of the company's common stock, which were issued in connection with a registered direct offering. The date of the first sale is reported as January 30, 2024, and the offering is not intended to last more than one year. Seelos Therapeutics has claimed an exemption under Rule 506(b) and has not yet sold any securities in this offering. The company has also disclosed sales commission expenses estimated at $280,000 and finder's fees of $65,000. The proceeds from the offering are not intended for payments to any executive officers, directors, or promoters. The filing includes signatures from key executives, including Michael Golembiewski, the Chief Financial Officer of Seelos Therapeutics.